NCT03093116 2026-05-27TRIDENT-1Turning Point Therapeutics, Inc.Phase 1/2 Recruiting500 enrolled 2 FDA
NCT04541082 2025-12-18Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System NeoplasmsJazz PharmaceuticalsPhase 1 Recruiting102 enrolled